Reviewer's report

Title: Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China

Version: 7 Date: 22 June 2015

Reviewer: Ryan Cassaday

Reviewer's report:

The authors appear to have addressed most of my previously-stated concerns. I was unable to find a detailed listing of the revisions made, which would have made it easier to identify where they occurred, but I was able to identify them nevertheless.

Major Compulsory Revisions:
Nothing additional

Minor Essential Revisions:
1. On page 8, line 333: The rates of anemia and thrombocytopenia were not "identical". Instead, please use a phrase such as "not different" or "similar".

Discretionary Revisions:
Nothing additional

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests